HGEN - Humanigen says ACTIV-5 trial is not suspended after earlier confusion

Humanigen (HGEN) earlier Tweeted that a trial for ACTIV-5 is not suspended after clinicaltrials.gov incorrectly listed the study as "suspended" on the order of IRB. The shares dropped 6.4% on the confusion.Humanigen said it confirmed that the trial is active and enrolling and has been assured that the mistake will be corrected. NIH has contacted clinicaltrials.org to rectify the issue, though there may be a lag in the update.Earlier, Humanigen announces it was awarded two patents in U.S.Recall Oct. 29, Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19.

For further details see:

Humanigen says ACTIV-5 trial is not suspended after earlier confusion